@jacoboestreichercoaching's peptide therapy claims checked

What did @jacoboestreichercoaching actually say?

The creator's core argument is that MK-677 is a bad idea, especially for young, undertrained people. His specific claims: it "could literally fuck up your insulin sensitivity forever," it could "potentially give you type 2 diabetes," it "didn't pass clinical trials," and there are "no current long-term studies" on it. He directed most of his frustration at teenagers who haven't trained seriously yet and want a shortcut. That's the actual argument here, not a blanket anti-peptide stance.

He also recommended a fairly specific alternative: four to five years of consistent training, calorie tracking, eight hours of sleep, and a high-protein whole-foods diet before even considering performance-enhancing drugs. The framing is harm reduction aimed at beginners, not a clinical analysis of MK-677's risk profile.

Does the science back this up?

On insulin sensitivity, the creator is largely correct, and this is well-documented. MK-677 is a ghrelin mimetic and growth hormone secretagogue. Elevated growth hormone and IGF-1 are known to antagonize insulin signaling. Multiple controlled studies have confirmed this signal.

Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed that MK-677 administration significantly increased fasting blood glucose and reduced insulin sensitivity in healthy adults after just two weeks. A longer 12-month trial by Murphy et al. (1998, same journal) in elderly subjects found persistent insulin resistance throughout the treatment period. These aren't fringe findings. The insulin effect is one of the more replicated observations in the MK-677 literature.

The "failed clinical trials" claim is trickier. MK-677 (ibutamoren) has been studied in clinical trials for muscle wasting, growth hormone deficiency, and hip fracture recovery. It has not received FDA approval, but "failed clinical trials" isn't quite the same as "was never tested." Some trials were discontinued for metabolic safety reasons. The distinction matters.

What did they get wrong (or right)?

The insulin sensitivity and diabetes risk claim is credible and backed by the literature. Credit where it's due.

But "they didn't pass clinical trials" is imprecise in a way that matters. Merck and Aeterna Zentaris conducted multiple Phase 2 and Phase 3 trials with ibutamoren. A notable example is the Phase 3 trial in hip fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics), which showed some efficacy signals but raised safety concerns including edema and congestive heart failure in older subjects. The compound hasn't been approved, but saying it "didn't pass" implies a single clean rejection. The reality is messier: some trials showed benefit, some raised safety flags, and development was halted for commercial and safety reasons combined.

The "no current long-term studies" claim is also overstated. There are studies up to 24 months. What he probably means is there are no long-term safety studies in healthy young adults using it for bodybuilding purposes, which is true and actually the more important point he should have made.

What should you actually know?

MK-677 is not approved by the FDA. It is not a SARM, despite being marketed alongside them. It works by mimicking ghrelin and stimulating pituitary GH release. The metabolic side effects, specifically insulin resistance, water retention, and increased appetite, are not rare or theoretical. They show up consistently in the controlled data.

The population this creator is addressing, young, undertrained individuals hoping for muscle gains, is also the population with the least clinical data. Every trial that exists involved older adults, growth hormone-deficient patients, or people recovering from fractures. Extrapolating to a 16-year-old who trains inconsistently is genuinely unsupported by evidence.

Other documented side effects include edema, fatigue, and increased cortisol in some studies (Chapman et al., 1996, Journal of Clinical Endocrinology and Metabolism). The appetite stimulation is significant enough that it can work against body composition goals unless caloric intake is tightly managed, which, as the creator notes, most beginners are not doing.

If you are considering any growth hormone secretagogue, that conversation belongs with a licensed physician who can order baseline metabolic labs, not a TikTok comment section.